RxDoctor Payments DataLook up a doctor →

Gil Melmed, MD

Gastroenterology · Los Angeles, CANPI 1336102524

Payments from drug & device makers

$3,034,387in general payments, 2019–2025

Across 540 payments — averaging $5619.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.3M
  • Merck$761K
  • Pfizer$342K
  • Gilead$255K
  • Johnson & Johnson$138K
  • Janssen Research & Development, LLC$42K
  • plus $199K from 20 others
$73,649in research payments, 2019–2025

Across 34 payments — averaging $2166.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$45K
  • Pfizer$19K
  • Takeda Pharmaceuticals U.S.A., Inc.$9K
  • AbbVie$355

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,034,387 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$14,432
Medicare patients
70
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →